Otaki Yoichi, Ashikaga Takashi, Sasaoka Taro, Kurihara Ken, Yoshikawa Shunji, Isobe Mitsuaki
Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Cardiovasc Revasc Med. 2019 Feb;20(2):120-125. doi: 10.1016/j.carrev.2018.04.022. Epub 2018 Apr 27.
Long-term clinical outcomes of permanent polymer everolimus-eluting stent (PP-EES) implantation after rotational atherectomy (RA) have not been fully evaluated. We sought to investigate the long-term clinical outcomes of PP-EES implantation after RA and assess the impact of hemodialysis on this treatment strategy.
Patients who underwent percutaneous coronary intervention (PCI) with PP-EES at 22 institutions between January 2010 and December 2011 were enrolled in this multicenter, observational trial. From a total of 1918 registered patients, 113 patients with 115 de-novo lesions who underwent PCI with PP-EES following RA were retrospectively analyzed. The primary endpoint was a major adverse cardiac event (MACE) defined as the composite of cardiac death, non-fatal myocardial infarction (MI), and clinically driven target lesion revascularization (TLR).
Long-term follow-up was available for 112 patients (99.1%). The median follow-up period was 2.9 (interquartile range 1.9-3.6) years. The mean age of the patients was 72.3 ± 8.8 years and 64 patients (56.6%) had chronic kidney disease (≥stage 3, 42 on hemodialysis). The cumulative incidences of MACE, non-fatal MI, and TLR were 22.1%, 5.3%, and 10.6%, respectively. Cox's proportional hazards analysis showed that the independent predictors of TLR were hemodialysis and chronic total occlusion. (HR, 14.1; 95% CI, 1.74-155.5; p = 0.01, HR, 9.01; 95% CI, 1.34-62.5; p = 0.02).
PP-EES implantation after lesion modification by RA is considered to be a feasible treatment strategy for heavily calcified lesions. Hemodialysis and chronic total occlusion appeared to be associated with TLR.
在旋磨术(RA)后植入永久性聚合物依维莫司洗脱支架(PP-EES)的长期临床结局尚未得到充分评估。我们旨在研究RA后植入PP-EES的长期临床结局,并评估血液透析对该治疗策略的影响。
2010年1月至2011年12月期间在22家机构接受PP-EES经皮冠状动脉介入治疗(PCI)的患者被纳入这项多中心观察性试验。从总共1918名登记患者中,对113例有115处新发病变且在RA后接受PP-EES PCI的患者进行回顾性分析。主要终点是主要不良心脏事件(MACE),定义为心源性死亡、非致命性心肌梗死(MI)和临床驱动的靶病变血运重建(TLR)的复合事件。
112例患者(99.1%)获得长期随访。中位随访期为2.9(四分位间距1.9 - 3.6)年。患者的平均年龄为72.3±8.8岁,64例患者(56.6%)患有慢性肾脏病(≥3期,42例接受血液透析)。MACE、非致命性MI和TLR的累积发生率分别为22.1%、5.3%和10.6%。Cox比例风险分析显示,TLR的独立预测因素是血液透析和慢性完全闭塞。(风险比,14.1;95%置信区间,1.74 - 155.5;p = 0.01,风险比,9.01;95%置信区间,1.34 - 62.5;p = 0.02)。
RA病变修饰后植入PP-EES被认为是治疗严重钙化病变的可行治疗策略。血液透析和慢性完全闭塞似乎与TLR有关。